Jiang Shangqian, Dandu Chaitu, Geng Xiaokun
China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Brain Circ. 2020 Dec 29;6(4):248-253. doi: 10.4103/bc.bc_69_20. eCollection 2020 Oct-Dec.
Ischemia-reperfusion injury (IRI) is a series of multifactorial cellular events that lead to increased cellular dysfunction after the restoration of oxygen delivery to hypoxic tissue, which can result in acute heart failure and cerebral dysfunction. This injury is severe and would lead to significant morbidity and mortality and poses an important therapeutic challenge for physicians. Nitric oxide (NO) minimizes the deleterious effects of IRI on cells. NO donors, such as organic nitrates and sodium nitroprusside, are used systematically to treat heart failure, angina, and pulmonary hypertension. Inhaled NO gas was approved by the FDA in 1999 to treat hypoxic newborns, and its beneficial ameliorations reach outside the realm of lung disease. This review will summarize the clinical application of NO in IRI.
缺血再灌注损伤（IRI）是一系列多因素的细胞事件，在向缺氧组织恢复氧输送后会导致细胞功能障碍增加，这可能会导致急性心力衰竭和脑功能障碍。这种损伤很严重，会导致显著的发病率和死亡率，对医生构成重要的治疗挑战。一氧化氮（NO）可将IRI对细胞的有害影响降至最低。NO供体，如有机硝酸盐和硝普钠，被系统地用于治疗心力衰竭、心绞痛和肺动脉高压。吸入式NO气体于1999年获得美国食品药品监督管理局（FDA）批准用于治疗缺氧新生儿，其有益改善作用超出了肺部疾病领域。本综述将总结NO在IRI中的临床应用。
